Graviti Pharmaceuticals is an API and finished-dose manufacturer based in India. It holds 2 active US drug master files. Its most recent recorded inspection, by US FDA, closed on 3 February 2023 as NAI. Customs aggregates show $60.3M of exports covering 2,467 molecules to 2 destinations in 2025.
NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.
| Site | FDA FEI |
|---|---|
| Sangareddy, India | 3012932394 |
| Molecule | Regulators | Docs |
|---|---|---|
| Pantoprazole | US FDA | 2 |
Also appears on these molecule pages
| Regulator | Filings | GMP certificates |
|---|---|---|
| US FDA | 2 | None |
| Year | Revenue | Exports | Destinations |
|---|---|---|---|
| 2026 YTD | Not reported | $14.4M | 1 |
| 2025 | Not reported | $60.3M | 2 |
| 2024 | Not reported | $58.1M | 2 |
| 2023 | Not reported | $52.5M | 2 |
Export figures are customs aggregates. We do not publish the identity of any buyer.
Choose your molecules and target markets. Graviti Pharmaceuticals comes back tiered against every other supplier able to file there.
Start for free